Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

For many solid malignancies, lymph node (LN) involvement represents a harbinger of
distant metastatic disease and, therefore, an important prognostic factor. Beyond its utility as …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer
featured with high intra-tumoral heterogeneity and poor prognosis. To comprehensively …

Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in
patients. The basis of this disease heterogeneity has proved difficult to resolve due to poor …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

Most patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less
than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …